Feb 3, 2025, 14:07 | Blog

Elisa Agostinetto: The results of our translational research project on lobular breast cancer at BSMO25

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, posted on LinkedIn: "It has been…

Feb 3, 2025, 11:15 | Societies

Highlights from BSMO25

The 27th Annual Belgian Society of Medical Oncology (BSMO) Meeting 2025 took place in Bruges…

Jan 17, 2025, 14:35 | Science

Elisa Agostinetto: The Preferable-Effect trial is now out

Elisa Agostinetto, Medical Oncologist at the Brussels University Hospital, posted on X, about recent paper…

Jan 13, 2025, 15:28 | Insight

CAR-T cell therapy for breast cancer: Current status and future perspective

A recent paper by Giuseppe Buono, Medical Doctor at IRCCS National Cancer Institute "Fondazione G.…

Jan 13, 2025, 10:23 | Science

The Randomized Noninferiority Phase III EMERALD Trial on HER2+ Locally Advanced/Metastatic Breast Cancer

A recent paper by Toshinari Yamashita et al. was published in the Journal of Clinical…

Jan 5, 2025, 18:21 | Insight

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…

Dec 16, 2024, 17:51 | Insight

Best of 2024 SABCS - San Antonio Breast Cancer Symposium

The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…

Dec 16, 2024, 04:11 | Insight

Highlights from Day 4 of SABCS 2024

The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…

Dec 15, 2024, 03:45 | Insight

Elisa Agostinetto: San Antonio Breast Cancer Symposium is my favourite congress of the year

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…

Dec 14, 2024, 03:06 | Blog

PATINA trial: Phase III Trial of Palbociclib, Anti-HER2 Therapy, and Endocrine Therapy vs. Anti-HER2 Therapy and Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer

Pre-clinical data showed that CDK 4/6 inhibition plays a role in HER2+ disease. Phase 2…

Dec 13, 2024, 05:49 | Insight

Highlights from Day 3 of SABCS 2024

The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…

Dec 12, 2024, 20:55 | Opinion

Elisa Agostinetto: Very much awaited results of EMBER-3 at SABCS24

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…

Dec 12, 2024, 20:22 | Blog

Christos Sotiriou talks about TNBC Inter and intra-patient heterogeneity at SABCS24 translational workshop

Elisa Agostinetto shared on X: "At SABCS24 translational workshop Christos Sotiriou talks about TNBC Inter and…

Dec 12, 2024, 16:50 | Insight

Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer

Imlunestrant has been approved for the treatment of breast cancer. It is a next-generation, brain-penetrant,…

Dec 11, 2024, 19:12 | Insight

Highlights from Day 1 of SABCS 2024

The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…

Dec 4, 2024, 10:39 | Insight

Elisa Agostinetto: The Results of the NEOENDO Translational Study by Francesco Schettini, et al.

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared an article by…

Nov 30, 2024, 14:02 | Insight

First Results of the Dutch SONIA Trial on CDK4/6 Inhibitors

Evaluating the Impact of CDK4/6 Inhibitors in First- and Second-Line Endocrine Therapy for HR+, HER2-…

Nov 23, 2024, 14:08 | Insight

Best of European Cancer Summit 2024: “United Against Cancer: Forging New Frontiers”

The European Cancer Summit 2024 took place on November 20 and 21, 2024, at the…

Nov 21, 2024, 17:20 | Insight

Elisa Agostinetto: Young Cancer Professionals meeting at the European Cancer Summit

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…

Nov 21, 2024, 14:08 | Blog

Highlights from European Cancer Summit 2024: Day 1

The European Cancer Summit 2024 is ongoing from November 20 and 21, 2024, at the…

Nov 16, 2024, 09:31 | Blog

OncoInfluencers to Follow on Social Media: Dr. Elisa Agostinetto

We’re excited to feature Dr. Elisa Agostinetto, a rising star in breast cancer research and…

Nov 15, 2024, 08:06 | Insight

Elisa Agostinetto: Axillary surgery in patients with residual isolated tumor cells after NACT for early breast cancer

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on…

Nov 8, 2024, 06:58 | Insight

Elisa Agostinetto: Camizestrant vs Fulvestrant for estrogen receptor-positive, HER2-negative breast cancer

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared an article by…

Nov 5, 2024, 14:29 | Blog

Did Michelangelo paint a woman with breast cancer in the Sistine Chapel in Rome?

Elisa Agostinetto posted on X about recent paper by Andreas G. Nerlich et al., titled…

Nov 2, 2024, 12:01 | Positive

Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…

Oct 27, 2024, 19:47 | Blog

Elisa Agostinetto: Endeavour Breast Cancer Program - One of the most beautiful experiences

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on LinkedIn:…

Oct 19, 2024, 12:22 | Blog

Elisa Agostinetto: EBCTCG analysis showing a major in recurrence rates for breast cancer clinical trials between 1990-2009

Elisa Agostinetto shared a post on X: ''Out in The Lancet an EBCTCG analysis showing…

Oct 13, 2024, 18:07 | Blog

Elisa Agostinetto: Gary Deng's 6 pillars for good health

Elisa Agostinetto shared a post about a recent seminar with Gary Deng about integrative oncology.…

Oct 8, 2024, 15:41 | Insight

Elisa Agostinetto: Association between hormonal contraceptives and breast cancer risk in BRCA1 carriers

Elisa Agostinetto shared a post on X: “Out in Journal of Clinical Oncology: A pooled…

Oct 8, 2024, 13:11 | Blog

Elisa Agostinetto: The practice-changing results of the HypoG-01 UNICANCER trial at ESMO24

Elisa Agostinetto shared a post by MediMix, on X, adding: ''At ESMO24 the practice-changing results…

Oct 3, 2024, 18:09 | Blog

Presidential Highlight from ESMO 2024

Elisa Agostinetto shared a post by MediMix on LinkedIn, adding: "At ESMO24 the practice-changing results of the HypoG-01…

Sep 25, 2024, 16:31 | Blog

Elisa Agostinetto: Datopotamab-Deruxtecan in HR+/HER2-low or negative metastatic breast cancer

Elisa Agostinetto shared a post on X: ''A press release from industry announces that TROPION-Breast01…

Sep 23, 2024, 00:12 | Insight

Elisa Agostinetto: FDA has approved adjuvant ribociclib based on the results of the NATALEE trial presented at ESMO24

Elisa Agostinetto shared a post by MediMix on LinkedIn, adding: “FDA has just approved adjuvant…

Sep 21, 2024, 09:35 | Blog

Elisa Agostinetto: Characteristics and clinical outcomes of breast cancer

Elisa Agostinetto shared a post on X, about recent paper published in ESMO Open: Characteristics…

Sep 19, 2024, 14:24 | Insight

Elisa Agostinetto: FDA has approved ribociclib with an AI for the adjuvant treatment of HR+/HER2-negative breast cancer

Elisa Agostinetto shared a post on X: “Novartis today announced that the FDA has approved…

Sep 18, 2024, 11:27 | Blog

Elisa Agostinetto: Triple negative breast cancer, not so negative anymore

Elisa Agostinetto shared a post on LinkedIn: ''Triple negative breast cancer: not so negative anymore!…

Sep 16, 2024, 16:31 | Societies

40 Posts Not To Miss From ESMO24 Day 3

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…

Sep 14, 2024, 17:15 | Societies

45 Posts not to miss from ESMO24 Day 1

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…

Aug 31, 2024, 14:15 | Insight

Tumour-agnostic authorised indications by FDA and EMA

Elisa Agostinetto shared a post on X about a recent paper by Benedikt Westphalen et…

Aug 25, 2024, 09:49 | Insight

Elisa Agostinetto talks about immunotherapy at the International Breast Pathology Course in Mexico City

Elisa Agostinetto shared on LinkedIn: “It has been a real pleasure to talk about immunotherapy…

Aug 24, 2024, 13:02 | Insight

Elisa Agostinetto: CDH1 truncating mutations were associated with poor prognosis

Elisa Agostinetto shared a paper by Lounes Djerroudi et al. on X: "CDH1 alterations are…

Aug 14, 2024, 13:00 | Insight

Elisa Agostinetto: Immunotherapy has reshaped the cancer treatment paradigm

Elisa Agostinetto shared on X: “Immunotherapy has reshaped cancer treatment paradigm, but we still need…

Aug 14, 2024, 07:35 | Insight

Elisa Agostinetto: The sub-analysis of the EMERALD trial

Elisa Agostinetto shared on X: "The sub-analysis of the EMERALD trial by Prior Duration of…

Aug 14, 2024, 07:33 | Insight

Olanzapine as antiemetic prophylaxis in chemotherapy

Elisa Agostinetto shared on X: "Olanzapine as antiemetic prophylaxis in chemotherapy. In this randomized phase…

Aug 11, 2024, 13:12 | Insight

Bilateral Mastectomy and Breast Cancer Mortality

Elisa Agostinetto shared on X about a recent paper titled "Bilateral Mastectomy and Breast Cancer Mortality"…

Aug 9, 2024, 17:49 | Insight

Soraia Lobo-Martins: Tumour Heterogeneity in Molecular Imaging for Breast Cancer

Soraia Lobo-Martins, Medical Research Fellow at Jules Bordet Institute, shared on X: "Excited to share…

Aug 4, 2024, 11:23 | Blog,Insight

Elisa Agostinetto: How to be a good mentor? - A truthful piece by Stefan Neubauer

Elisa Agostinetto shared a post on X about an article by Stefan Neubauer titled "How…

Aug 3, 2024, 10:26 | Blog

Elisa Agostinetto: Many opportunities for young cancer professionals in European Union to build worldwide collaborations

Elisa Agostinetto shared a post by European Cancer Organisation on LinkedIn, adding: “Join us. Many…

Jul 26, 2024, 00:03 | Blog

Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522

Elisa Agostinetto shared on X: "Out in JCO a must-read by Marleen Kok on the…

Jul 19, 2024, 14:02 | Insight

The results of the IMpassion132 trial

Elisa Agostinetto shared on X a paper by Rebecca Dent et al. titled "IMpassion132 double-blind…

Jul 10, 2024, 12:55 | Blog

Elisa Agostinetto: 10 key pressure points in the delivery of cancer care that need to be urgently addressed

Elisa Agostinetto shared a policy review by Ajay Aggarwal on X, adding the following: “Out…

Jul 7, 2024, 09:35 | Insight

Final outcome analysis from TUXEDO-1 trial is out

Elisa Agostinetto shared a paper by Rupert Bartsch et al. on X: “Now out the…

Jun 25, 2024, 07:12 | Blog

Elisa Agostinetto and Giuseppe Curigliano discuss the results of Destiny-Breast06

Elisa Agostinetto shared on LinkedIn: "At ASCO24 I met Prof Giuseppe Curigliano to discuss the results…

Jun 23, 2024, 02:25 | Blog

Elisa Agostinetto: Important data for patients who desire pregnancy after a diagnosis of breast cancer

Elisa Agostinetto shared a post by ESMO on X/Twitter: "Are assisted reproductive techniques safe in…

Jun 20, 2024, 11:58 | Insight

Elisa Agostinetto: A must-read for all oncologists

Elisa Agostinetto recently shared a post on X: "Published in 2023 and yet addressing a…

Jun 18, 2024, 15:34 | Blog

Elisa Agostinetto: Congrats to Matteo Lambertini for having organized a great YBO event

Elisa Agostinetto shared a post on X: “Congrats to Matteo Lambertini for having organized a great…

Jun 17, 2024, 20:15 | Insight

Elisa Agostinetto: Commentary on the updated results of DestinyBreast03

Elisa Agostinetto shared on X/Twitter: "Out commentary on the updated results of DestinyBreast03 is out…

Jun 2, 2024, 11:17 | Societies

Elisa Agostinetto: Do patients with ER-low (1-10%) tumors benefit from adjuvant ET?

Hope Rugo, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at…

May 20, 2024, 11:18 | Drugs

Elisa Agostinetto: Our review on emerging treatments for HER2+ breast cancer

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn: “Now…

May 19, 2024, 14:11 | Societies

20 Posts Not To Miss From ESMOBreast24!

ESMO Breast Cancer 2024 (ESMOBreast24) took place as an onsite and online event in Berlin,…

May 19, 2024, 13:38 | Insight

Elisa Agostinetto: I discussed the results of our work with Video Journal of Oncology at ESMOBreast24

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn: “At…

May 19, 2024, 02:10 | Societies

Key messages by Fabrice Andre at ESMOBreast24 session on ctDNA for clinical decision making

Elisa Agostinetto, Medical Oncologist and Research Physician at Jules Bordet, shared on X: . "At…

May 18, 2024, 08:47 | Blog

Elisa Agostinetto: At ESMO Breast24, Hope Rugo presents results of CAPItello-291

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…

May 18, 2024, 04:13 | Blog

Elisa Agostinetto: Is this a new predictive biomarker for PFS with camizestrant

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…

May 18, 2024, 02:04 | Insight

Elisa Agostinetto: At ESMO Breast24 Christine Desmedt presents an analysis of germline BRCA1/2 mutation

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on X: “At ESMO Breast24…

May 17, 2024, 15:08 | Societies

Elisa Agostinetto: our poster exploring histologic subtypes of early breast cancers at ESMOBreast24

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on X: "At ESMOBreast24, we…

May 8, 2024, 23:17 | Insight

Giampaolo Bianchini: Join us at the next ESMO Virtual Plenary session!

Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, shared a post by Giampaolo…

May 7, 2024, 06:28 | Insight

Elisa Agostinetto: The long and winding road to biomarkers for immunotherapy

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on LinkedIn: "The long and…

Apr 23, 2024, 10:13 | Blog

Nikolina Dodlek: We had an opportunity to host the 3rd European Cancer Organisation Young Cancer Professionals group meeting, 1st for this year

Nikolina Dodlek, Head Nurse Department for Oncology at University Hospital Centre Osijek, shared on LinkedIn:…

Apr 20, 2024, 14:18 | Blog

Elisa Agostinetto: The proportion of patients with an actionable alteration (AA) in serial cfDNA decreases with time

Elisa Agostinetto, Clinical Research Fellow at Jules Bordet Institute in Brussels, shared a post on…

Apr 15, 2024, 17:01 | Drugs

Elisa Agostinetto: It’s likely that adjuvant Pembrolizumab has a lower impact compared to neoadjuvant Pembrolizumab

Elisa Agostinetto, Research Physician at the Institute of Jules Bordet in Brussels, posted on X/Twitter:…

Apr 3, 2024, 15:19 | Insight

Elisa Agostinetto: A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC

Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, posted on X/Twitter: "Out…

Mar 29, 2024, 06:30 | Insight

Elisa Agostinetto: Important meta-analysis in NPJ Journals Breast shedding light on one of the biggest unmet needs in breast oncology

Elisa Agostinetto, Medical Oncologist and Research Fellow at Jules Bordet Institute in Brussels, posted on…

Mar 22, 2024, 22:58 | Blog

Elisa Agostinetto: Our subanalysis of the CLEOPATRA study led by Veronique Debien

Elisa Agostinetto, Clinical Research Fellow at Jules Bordet Institute in Brussels, shared a post on…

Mar 15, 2024, 15:38 | Blog

Elisa Agostinetto: Our last meta-analysis led by Guilherme Nader Marta shows that ctDNA detection in early breast cancer is associated with higher risk of recurrence

Elisa Agostinetto, Clinical Research Fellow at Jules Bordet Institute in Brussels, shared a post on…

Mar 12, 2024, 20:36 | Societies

Elisa Agostinetto: Happy to receive a ESMO Merit Travel Grant for the upcoming ESMO Breast24

Elisa Agostinetto, Research Fellow at Jules Bordet Institute in Brussels, shared a post on X/Twitter: "Happy to receive…

Feb 16, 2024, 18:13 | Blog

Elisa Agostinetto: Nice editorial out in Journal of Clinical Oncology on the design, analysis, and reporting of research that involves real-world data

Elisa Agostinetto, Research Fellow at Jules Bordet Institute, shared a post on X/Twitter: "Nice editorial out…

Jan 28, 2024, 18:29 | Blog

Elisa Agostinetto: Estradiol levels remain the biomarker of choice

Elisa Agostinetto, Clinical Research Fellow at the Institute Jules Bordet, recently shared on X/Twitter: "Out…

Dec 20, 2023, 12:00 | Insight

Elisa Agostinetto: Blinded independent central review (BICR) in clinical trials is it really needed

Elisa Agostinetto, Medical Research Fellow at Jules Bordet Institute in Brussels, recently posted X/Twitter: ''Blinded…

Dec 17, 2023, 17:26 | Blog

25 Posts Not To Miss From SABCS 2023

The San Antonio Breast Cancer Symposium 2023 (SABCS 2023) took place in San Antonio, Texas…

Nov 16, 2023, 17:35 | Blog

Daniel Portik: Full house at the Young Cancer Professionals meeting of the European Cancer Summit hosted by European Cancer Organisation

Daniel Portik, RTQA Fellow at EORTC, shared a post on LinkedIn: “Full house at the…

Oct 4, 2023, 21:11 | Blog

Elisa Agostinetto: Proud to be part of Institut Jules Bordet team and to work everyday with extraordinary colleagues and mentors to help fight against breast cancer.

Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared the following post on Twitter: "This…